Cicatrix
Conditions
Keywords
scar prevention, sectio, extract of allium cepae, allantoin, heparin
Brief summary
To investigate the efficacy of prophylactic use of a topical gel containing extract of allium cepae, allantoin and heparin after surgical removal of the primary cesarean scar in the second cesarean section.
Detailed description
120 patients who are admitted for the second cesarean delivery, not taking prophylactic medication after the first cesarean section, whose scar development and measurements are taken will be included in the study. First caesarean section scars will be removed surgically for all patients. 60 out of 120 patients (treatment group) will use prophylactic topical scar gel 2 times in a day, and remaining 60 patients (control group )won't use. The efficacy of the drug will be evaluated by taking strict measurements of the incision and POSAS (The Patient and Observer Scar Assessment Scale) and Vancouver Scales at 6.12 and 24 weeks. Steps; 1. Observation of the primary cesarean scar by taking scar measurements and using Vancouver and POSAS scales. 2. Surgical removal of the primary cesarean scar in the second cesarean section. 3. 24 weeks topical application of gel containing extract of allium cepae, allantoin and heparin(only treatment group). 4. Observation of the skin incision at 6,12 and 24 weeks by taking scar measurements with using Vancouver and POSAS scales.
Interventions
DRUGextract of allium cepae, allantoin and heparin
prophylactic use of a topical gel containing extract of allium cepae, allantoin and heparin two times in a day after second c-section
PROCEDUREScar excision
Scar excision in second c-section
Sponsors
Suleymaniye Birth And Women's Health Education And Research Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients who are admitted for the second cesarean delivery * Not to use topical scar gel after the first c-section
Exclusion criteria
* chronic illness, immunosuppressive therapy or smoking * development of wound infection during the second c- section * allergies and hypersensitivities to components of the gel
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| POSAS observer score change will be assessed by POSAS observer scale (The Patient and Observer Scar Assessment Scale v2.0) just prior to second c-section and at 6,12 and 24 weeks following the c-section. | just prior to second c-section and at 6,12,24 weeks |
| POSAS patient score change will be assessed by POSAS patient scale (The Patient and Observer Scar Assessment Scale v2.0) just prior to second c-section and at 6,12 and 24 weeks following the c-section. | just prior to second c-section and at 6,12,24 weeks |
| Vancouver scar score change will be assessed by Vancouver scar scale just prior to second c-section and at 6,12 and 24 weeks following the c-section. | just prior to second c-section and at 6,12,24 weeks |
Countries
Turkey (Türkiye)
Outcome results
None listed